Engineered Microbial‐Based Therapeutics Nose No Bounds: Extending Innovation to Rhinologic Disease Management

Advancements in synthetic biology provide an opportunity to deliver targeted and controllable precision therapy to address sinonasal diseases. By leveraging the natural microbial ecosystem of the nasal mucosa and its mutability, engineered therapeutic bacteria present a promising treatment modality currently underexplored in this field. Investigating the practical application of this emerging therapeutic option stands to enhance our management of rhinologic diseases. Synthetic biology enables us to address underlying inflammatory processes and sinonasal malignancies with bespoke microorganisms that facilitate localized microbiota modulation and immunomodulation. By harnessing the intrinsic regulatory properties of the native nasal microbiome, we can develop innovative strategies that not only improve treatment efficacy but also open new avenues for managing complex sinonasal conditions.